Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in Healthy Adults After Inhaled LPS Challenge
NCT05351671Phase 1Completed
- Sponsor
- ReAlta Life Sciences
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegtarazimod in severe asthma (3 arms), sponsored by ReAlta Life Sciences. Primary endpoint: Absolute Neutrophil Count in Induced Sputum at 24 hours. Started May 2022; status: completed.
02
Drugs
pegtarazimod
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT05351671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351671.